$43.68−2.25 (−4.90%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
Edgewise Therapeutics (EWTX) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business enginePre-revenue: no positive revenue in any year through FY25, so the growth and margin read is withheld. Worth your attention in FY25: Share count (+174.3%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)—
0.0
FY21→FY25CAGR —
Net income ($M)▼25.4%
−167.8
FY21→FY25CAGR —
Free cash flow ($M)▼30.6%
−144.1
FY21→FY25CAGR —
Diluted EPS▼12.4%
−1.63
no value for 2 of 5 yearsCAGR —
What the receipts whisper · what a headline number hides
Share count
+174.3%
37.5mn → 102.9mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex
$256.0K
−80.5% YoY in FY25.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
Margin trend · direction beats level
This filer reports no gross profit or operating income line, so those margins are not drawn.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Cost of revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Research & development | 165,368.0 | 151,389.0 | 126,966.0 | 90,905.0 | 54,032.0 | 32,189.0 | ▲19.2% | +47.3% |
Selling, general & admin | 52,812.0 | 40,017.0 | 31,866.0 | 23,452.0 | 17,626.0 | 11,026.0 | ▲25.6% | +38.0% |
Total operating expenses | 218,180.0 | 191,406.0 | 158,832.0 | 114,357.0 | 71,658.0 | 43,215.0 | ▲20.5% | +45.1% |
Operating incomefeeds ROC rank | −218,180.0 | −191,406.0 | −158,832.0 | −114,357.0 | −71,658.0 | −43,215.0 | ▼20.5% | — |
Other income, net | 1,383,108.0 | 23,611.0 | 25,019.0 | 14,194.0 | 4,018.0 | 402.0 | — | — |
Pretax income | 1,164,928.0 | −167,795.0 | −133,813.0 | −100,163.0 | −67,640.0 | −42,813.0 | ▼25.4% | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | 1,009,595.0 | −167,795.0 | −133,813.0 | −100,163.0 | −67,640.0 | −42,813.0 | ▼25.4% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | 8.19 | −1.63 | −1.45 | −1.57 | — | — | ▼12.4% | — |
Diluted shares (mn) | 120.87 | 102.93 | 92.41 | 63.72 | 53.59 | 37.53 | ▲11.4% | +28.7% |
| Margins | ||||||||
† TTM = trailing four quarters through 2026-09-30.
1 more year of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

